The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis

Authors :: Jeffrey A, Tice
Daniel R, Touchette
Pei-Wen, Lien
Foluso, Agboola
Dmitriy, Nikitin
Steven D, Pearson
Source :: Journal of managed carespecialty pharmacy. 28(1)
Publication Year :: 2021

Subjects :: Complement Inactivating Agents
Models, Economic
Treatment Outcome
Cost-Benefit Analysis
Myasthenia Gravis
Humans
Antibodies, Monoclonal, Humanized
Antibodies

Tools